Newsletter

Axxess’ Sorpon® OTC fungal shampoo generated 600,000 in 2010 sales, only grabbing a small portion of the 10 mil Canadian market.

Gravergol®, a prescription migraine product did 400,000 in 2010 sales. The Canadian market is more the 2 mil

Axxess’ Triferexx is a high-dose oral iron supplement that generated 2mil in sales in 2010 with limited marketing under the previous management. In Canada alone, the market size is estimated between 15mil and 20mil. To showcase the potential, Feramax, a competitor supplement marketed by BioSyent, generated 5mil in sales in 2012, up almost 80 percent from 2011.

Axxess pharma (AXXE) has licensed Monurol a single dose antibiotic, specific treatment for Urinary track infections with Zambon SPA Switzerland. And exclusive license for marketing, and distribution of Trans dermal patches, and cosmetic masks and patches with Caleb Pharma.

The global pharmaceuticals market is worth US$300B a year, a figure expected to rise to US$400B within three years. 

Axxess Pharms  23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more.

Axxess Pharma intends to market these products with affordable pricing and widespread availability. Our company will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients we serve, and also foster innovation in education, leadership and advocacy.

Mass distribution is expected in the States in the fall of 2014. Distribution in Mexico is expected a year later. While the company targets North American distribution at leading retailers such as Walmart, Shoppers Drug Mart, CVS, Walgreens and more, online distribution will generate sales through the company’s site, Amazon.com, UFC.com, etc.

Time to start your due diligence on AXXE

See you at the Bell!  

wallstreetstallions has been compensated by a third party, five thousand dollars, for this email advertisement.